ICER thresholds

Market Access

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.